Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Head and Neck Cancer|Stomatitis|Mucositis|Pneumonia, Ventilator-Associated
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00022373 |
CDR0000068810 | P3 |
Unknown status |
Head and Neck Cancer|Stomatitis|Mucositis |
None |
2019-03-21 |
Treatments |
|
NCT00118781 |
NCT00118781 | P3 |
Terminated |
Pneumonia, Ventilator-Associated |
None |
2019-03-21 |
Treatments |